EQT and ADIA completed the acquisition of Dechra Pharmaceuticals for £4.88bn.

EQT, a private equity company, and ADIA, a sovereign wealth fund, completed the acquisition of Dechra Pharmaceuticals, a pharmaceutical company, for £4.88bn. "We plan to support Dechra's talented management team accelerating their business strategy and long-term growth in an increasingly competitive environment by providing, where needed, additional investment in its innovative pipeline and further supporting global expansion. We believe that private ownership will enable Dechra's management team to take a longer-term view as it focuses on accelerating growth," Anthony Santospirito, EQT Partner.